Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 172821, 7 pages
http://dx.doi.org/10.1155/2014/172821
Review Article

TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease

1Département d'Hépatogastroentérologie, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier, France
2Département d’Immunologie, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France

Received 28 June 2013; Revised 15 January 2014; Accepted 17 February 2014; Published 18 March 2014

Academic Editor: Sophie Desplat-Jégo

Copyright © 2014 Romain Altwegg and Thierry Vincent. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Danese, J. F. Colombel, L. Peyrin-Biroulet, P. Rutgeerts, and W. Reinisch, “Review article: the role of anti-TNF in the management of ulcerative colitis—past, present and future,” Alimentary Pharmacology & Therapeutics, vol. 37, no. 9, pp. 855–866, 2013. View at Google Scholar
  2. L. Peyrin-Biroulet and M. Lémann, “Review article: remission rates achievable by current therapies for inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 8, pp. 870–879, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. E. A. Maser, R. Villela, M. S. Silverberg, and G. R. Greenberg, “Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease,” Clinical Gastroenterology and Hepatology, vol. 4, no. 10, pp. 1248–1254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. C. H. Seow, A. Newman, S. P. Irwin, A. H. Steinhart, M. S. Silverberg, and G. R. Greenberg, “Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis,” Gut, vol. 59, no. 1, pp. 49–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Baert, M. Noman, S. Vermeire et al., “Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease,” The New England Journal of Medicine, vol. 348, no. 7, pp. 601–608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Afif, E. V. Loftus Jr., W. A. Faubion et al., “Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 105, no. 5, pp. 1133–1139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Monteleone, F. Pallone, and G. Monteleone, “Th17-related cytokines: new players in the control of chronic intestinal inflammation,” BMC Medicine, vol. 9, article 122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Mueller, “Tumour necrosis factor in mouse models of chronic intestinal inflammation,” Immunology, vol. 105, no. 1, pp. 1–8, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. MacEwan, “TNF receptor subtype signalling: differences and cellular consequences,” Cellular Signalling, vol. 14, no. 6, pp. 477–492, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Wajant, K. Pfizenmaier, and P. Scheurich, “Tumor necrosis factor signaling,” Cell Death and Differentiation, vol. 10, no. 1, pp. 45–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. R. M. Aspalter, M. M. Eibl, and H. M. Wolf, “Regulation of TCR-mediated T cell activation by TNF-RII,” Journal of Leukocyte Biology, vol. 74, no. 4, pp. 572–582, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Dahlen, H. Strid, A. Lundgren et al., “Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis,” Scandinavian Journal of Immunology, vol. 78, no. 3, pp. 275–284, 2013. View at Publisher · View at Google Scholar
  13. X. Chen, X. Wu, Q. Zhou, O. M. Howard, M. G. Netea, and J. J. Oppenheim, “TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment,” Journal of Immunology, vol. 190, no. 3, pp. 1076–1084, 2013. View at Google Scholar
  14. X. Chen and J. J. Oppenheim, “Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity,” FEBS Letters, vol. 585, no. 23, pp. 3611–3618, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Wang, G. Han, Y. Dou et al., “Opposite role of tumor necrosis factor receptors in dextran sulfate sodium-induced colitis in mice,” PLoS ONE, vol. 7, no. 12, Article ID e52924, 2012. View at Google Scholar
  16. S. Danese, J.-F. Colombel, W. Reinisch, and P. J. Rutgeerts, “Review article: infliximab for Crohn's disease treatment—shifting therapeutic strategies after 10 years of clinical experience,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 8, pp. 857–869, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. B. Hanauer, A. A. Kornbluth, J. Messick, D. T. Rubin, W. J. Sandborn, and B. E. Sands, “Clinical scenarios in IBD: optimizing the use of conventional and biologic agents,” Inflammatory Bowel Diseases, vol. 16, no. 1, pp. S1–S11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Billiet, P. Rutgeerts, M. Ferrante, G. Van Assche, and S. Vermeire, “Targeting TNF-alpha for the treatment of inflammatory bowel disease,” Expert Opinion on Biological Therapy, vol. 14, no. 1, pp. 75–101, 2014. View at Google Scholar
  19. S. R. Targan, S. B. Hanauer, S. J. H. Van Deventer et al., “A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease,” The New England Journal of Medicine, vol. 337, no. 15, pp. 1029–35, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Dignass, G. Van Assche, J. O. Lindsay et al., “The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management,” Journal of Crohn's and Colitis, vol. 4, no. 1, pp. 28–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Dignass, J. O. Lindsay, A. Sturm et al., “Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management,” Journal of Crohn's and Colitis, vol. 6, no. 10, pp. 991–1030, 2012. View at Google Scholar
  22. J. S. Hyams, T. Lerer, A. Griffiths et al., “Outcome following infliximab therapy in children with ulcerative colitis,” The American Journal of Gastroenterology, vol. 105, no. 6, pp. 1430–1436, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Hyams, W. Crandall, S. Kugathasan et al., “Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children,” Gastroenterology, vol. 132, no. 3, pp. 863–873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. R. K. Russell, M. L. Wilson, S. Loganathan et al., “A british society of paediatric gastroenterology, hepatology and nutrition survey of the effectiveness and safety of Adalimumab in children with inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 8, pp. 946–953, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Mian and H. Baron, “Adalimumab, a novel anti-tumor necrosis factor-α antibody in a child with refractory Crohn's disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 41, no. 3, pp. 357–359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. F. Colombel, W. J. Sandborn, W. Reinisch et al., “Infliximab, azathioprine, or combination therapy for Crohn's disease,” The New England Journal of Medicine, vol. 362, no. 15, pp. 1383–1395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. B. E. Sands, M. A. Blank, K. Patel, and S. J. Van Deventer, “Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study,” Clinical Gastroenterology and Hepatology, vol. 2, no. 10, pp. 912–920, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. J.-F. Colombel, W. J. Sandborn, P. Rutgeerts et al., “Adalimumab for maintenance of clinical response and remission inpatients with Crohn's disease: the CHARM Trial,” Gastroenterology, vol. 132, no. 1, pp. 52–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Schreiber, P. Rutgeerts, R. N. Fedorak et al., “A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease,” Gastroenterology, vol. 129, pp. 807–818, 2005. View at Google Scholar · View at Scopus
  30. W. J. Sandborn, B. G. Feagan, C. Marano et al., “Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis,” Gastroenterology, vol. 146, no. 1, pp. 96.e1–109.e1, 2014. View at Google Scholar
  31. W. J. Sandborn, B. G. Feagan, C. Marano et al., “Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis,” Gastroenterology, vol. 146, no. 1, pp. 85–95, 2014. View at Google Scholar
  32. F. Schnitzler, H. Fidder, M. Ferrante et al., “Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort,” Gut, vol. 58, no. 4, pp. 492–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Yanai and S. B. Hanauer, “Assessing response and loss of response to biological therapies in IBD,” The American Journal of Gastroenterology, vol. 106, no. 4, pp. 685–698, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Van Assche, C. Magdelaine-Beuzelin, G. D'Haens et al., “Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial,” Gastroenterology, vol. 134, no. 7, pp. 1861–1868, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Billioud, W. J. Sandborn, and L. Peyrin-Biroulet, “Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review,” The American Journal of Gastroenterology, vol. 106, no. 4, pp. 674–684, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. W. J. Sandborn, J.-F. Colombel, S. Schreiber et al., “Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics,” Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 141–151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Peyrin-Biroulet, P. Deltenre, N. de Suray, J. Branche, W. J. Sandborn, and J.-F. Colombel, “Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials,” Clinical Gastroenterology and Hepatology, vol. 6, no. 6, pp. 644–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. A. Fasanmade, O. J. Adedokun, M. Blank, H. Zhou, and H. M. Davis, “Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 Phase III clinical trials,” Clinical Therapeutics, vol. 33, no. 7, pp. 946–964, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. A. Fasanmade, O. J. Adedokun, J. Ford et al., “Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis,” European Journal of Clinical Pharmacology, vol. 65, no. 12, pp. 1211–1228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Ordás, D. R. Mould, B. G. Feagan, and W. J. Sandborn, “Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms,” Clinical Pharmacology and Therapeutics, vol. 91, no. 4, pp. 635–646, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. K. S. Nanda, A. S. Cheifetz, and A. C. Moss, “Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis,” The American Journal of Gastroenterology, vol. 108, no. 1, pp. 40–47, 2013. View at Google Scholar
  42. Z. Xu, K. Seitz, A. Fasanmade et al., “Population pharmacokinetics of infliximab in patients with ankylosing spondylitis,” Journal of Clinical Pharmacology, vol. 48, no. 6, pp. 681–695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. C. Moss, V. Brinks, and J. F. Carpenter, “Review article: immunogenicity of anti-TNF biologics in IBD—the role of patient, product and prescriber factors,” Alimentary Pharmacology & Therapeutics, vol. 38, no. 10, pp. 1188–1197, 2013. View at Google Scholar
  44. S. Vermeire, M. Noman, G. Van Assche, F. Baert, G. D'Haens, and P. Rutgeerts, “Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease,” Gut, vol. 56, no. 9, pp. 1226–1231, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Bortlik, D. Duricova, K. Malickova et al., “Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease,” Journal of Crohn's and Colitis, vol. 7, no. 9, pp. 736–743, 2012. View at Google Scholar
  46. C. Steenholdt, K. Bendtzen, J. Brynskov, O. Ø. Thomsen, and M. A. Ainsworth, “Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease,” Scandinavian Journal of Gastroenterology, vol. 46, no. 3, pp. 310–318, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Hibi, A. Sakuraba, M. Watanabe et al., “Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease,” Inflammatory Bowel Diseases, vol. 18, no. 8, pp. 1480–1487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. O. J. Adedokun, Z. Xu, L. Padgett et al., “Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study,” Inflammatory Bowel Diseases, vol. 19, no. 13, pp. 2753–2762, 2013. View at Google Scholar
  49. S. Paul, E. Del Tedesco, H. Marotte et al., “Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study,” Inflammatory Bowel Diseases, vol. 19, no. 12, pp. 2568–2576, 2013. View at Publisher · View at Google Scholar
  50. S. Ben-Horin, M. Yavzori, L. Katz et al., “The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful,” Gut, vol. 60, no. 1, pp. 41–48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. M. A. Ainsworth, K. Bendtzen, and J. Brynskov, “Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease,” The American Journal of Gastroenterology, vol. 103, no. 4, pp. 944–948, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Imaeda, S. Bamba, K. Takahashi et al., “Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment,” Journal of Gastroenterology. In press.
  53. B. Pariente, G. P. De Chambrun, R. Krysiek et al., “Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 18, no. 7, pp. 1199–1206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Cassinotti and S. Travis, “Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review,” Inflammatory Bowel Diseases, vol. 15, no. 8, pp. 1264–1275, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. S. B. Hanauer, C. L. Wagner, M. Bala et al., “Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease,” Clinical Gastroenterology and Hepatology, vol. 2, no. 7, pp. 542–553, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Karmiris, G. Paintaud, M. Noman et al., “Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease,” Gastroenterology, vol. 137, no. 5, pp. 1628–1640, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. L. Chiu, D. T. Rubin, S. Vermeire et al., “Serum adalimumab concentration and clinical remission in patients with Crohn's disease,” Inflammatory Bowel Diseases, vol. 19, no. 6, pp. 1112–1122, 2013. View at Google Scholar
  58. X. Roblin, H. Marotte, M. Rinaudo et al., “Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases,” Clinical Gastroenterology and Hepatology, vol. 12, no. 1, pp. 80.e2–84.e2, 2014. View at Google Scholar
  59. G. M. Bartelds, C. A. Wijbrandts, M. T. Nurmohamed et al., “Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 921–926, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. R. L. West, Z. Zelinkova, G. J. Wolbink, E. J. Kuipers, P. C. F. Stokkers, and C. J. Van Der Woude, “Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 9, pp. 1122–1126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Imaeda, K. Takahashi, T. Fujimoto et al., “Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease,” Journal of Gastroenterology, vol. 49, no. 1, pp. 100–109, 2014. View at Publisher · View at Google Scholar
  62. G. M. Bartelds, C. L. M. Krieckaert, M. T. Nurmohamed et al., “Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm follow-up,” Journal of the American Medical Association, vol. 305, no. 14, pp. 1460–1468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Vermeire and A. Gils, “Value of drug level testing and antibody assays in optimising biological therapy,” Frontline Gastroenterology, vol. 4, no. 1, pp. 41–43, 2013. View at Google Scholar
  64. I. Cleynen and S. Vermeire, “Paradoxical inflammation induced by anti-TNF agents in patients with IBD,” Nature Reviews Gastroenterology & Hepatology, vol. 9, no. 9, pp. 496–503, 2012. View at Google Scholar
  65. S. Ben-Horin, M. Waterman, U. Kopylov et al., “Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 11, no. 4, pp. 444–447, 2013. View at Google Scholar
  66. C. Steenholdt, M. Al-khalaf, J. Brynskov, K. Bendtzen, O. Thomsen, and M. A. Ainsworth, “Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 18, no. 12, pp. 2209–2217, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Vande Casteele, A. Gils, S. Singh et al., “Antibody response to infliximab and its impact on pharmacokinetics can be transient,” The American Journal of Gastroenterology, vol. 108, no. 6, pp. 962–971, 2013. View at Publisher · View at Google Scholar
  68. B. Ungar, Y. Chowers, M. Yavzori et al., “The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab,” Gut, 2013. View at Publisher · View at Google Scholar
  69. F. S. Velayos, J. G. Kahn, W. J. Sandborn, and B. G. Feagan, “A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's Disease who lose responsiveness to infliximab,” Clinical Gastroenterology and Hepatology, vol. 11, no. 6, pp. 654–666, 2013. View at Google Scholar
  70. C. Steenholdt, J. Brynskov, O. O. Thomsen et al., “Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial,” Gut, 2013. View at Publisher · View at Google Scholar
  71. N. Vande Casteele, D. J. Buurman, M. G. Sturkenboom et al., “Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays,” Alimentary Pharmacology & Therapeutics, vol. 36, no. 8, pp. 765–771, 2012. View at Google Scholar
  72. D. J. Buurman, N. Vande Casteele, M. G. Sturkenboom et al., “Letter: detection of infliximab levels and anti-infliximab antibodies—comparison of three different assays, authors' reply,” Alimentary Pharmacology & Therapeutics, vol. 37, no. 2, p. 282, 2013. View at Google Scholar
  73. E. Parussini, “Letter: detection of infliximab levels and anti-infliximab antibodies—comparison of three different assays,” Alimentary Pharmacology & Therapeutics, vol. 37, no. 2, p. 281, 2013. View at Google Scholar